Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of blood cancer called Philadelphia chromosome-positive chronic myeloid leukemia (CML) in its early ("chronic") phase, before starting treatment
- People who are currently taking one of the following targeted cancer medicines: imatinib, nilotinib, or bosutinib (these are known as first- or second-generation tyrosine kinase inhibitors)
- People who have given their written agreement to take part in the study
Who may not be able to join:
- People who have previously had a stroke
- People who have previously had a heart attack
- People who have Type 1 or Type 2 diabetes
- People who have chronic kidney disease (any stage, from mild to kidney failure)
- People who have coronary heart disease with noticeable symptoms (moderate to severe, classified as functional class II–IV)
- People who have severe high blood pressure (classified as Grade 3 hypertension)
- People who have been found to have fatty plaque build-up in the arteries of their arms or legs, based on a specific ultrasound scan
- People who have an irregular or rapid heart rhythm condition known as atrial fibrillation or atrial flutter
- People who have another type of cancer in addition to CML
- People who have an active inflammatory disease (confirm with trial site)
- People whose cancer has developed certain genetic changes that mean the targeted medicines listed above would not be expected to work (drug resistance mutations)
- People who decline to undergo the required examinations for the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sabina Cherenova, Samara State Medical University
Phone: +78463741004
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluation of type of microcirculation.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.